Veracyte Inc. announced it will release financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after the close of market.

Company management will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 pm Eastern Time on the same day. The live webcast will be accessible via the company's website, with a replay available following the broadcast conclusion.

Company Profile

Veracyte is a global diagnostics company focused on transforming cancer care. Its molecular tests assess tumor biology to assist clinicians in making essential care decisions. The company’s Diagnostics Platform integrates genomic and clinical data, advanced bioinformatics, AI, and evidence-generation engines to support innovation and pipeline development.

The portfolio includes several key tests:

• Afirma Genomic Sequencing Classifier
• Decipher Bladder Genomic Classifier
• Decipher Prostate Genomic Classifier
• Prosigna Breast Risk of Recurrence test
• TrueMRD Monitoring Test for MIBC

Investor Relations

Investors and media may contact the company through the designated channels provided in the announcement for further inquiries regarding the upcoming earnings release.

Veracyte, Inc. (NASDAQ: VCYT) has agreed to acquire Convergent Genomics in a transaction valued at $150 million in upfront cash. The deal secures the UroAmp platform, which utilizes proprietary urinary tumor DNA technology for bladder cancer diagnostics.

The acquisition integrates Convergent’s UroAmp platform into Veracyte’s existing product portfolio. UroAmp has been clinically validated for non-muscle invasive bladder cancer (NMIBC), covering therapy-response monitoring and post-treatment surveillance. This addresses a significant patient population, with approximately 65,000 new NMIBC diagnoses annually in the U.S. out of 85,000 total bladder cancer cases.

Deal Structure And Financial Terms

The total consideration comprises $150 million paid immediately in cash. An additional $30 million is contingent upon achieving specific milestones related to UroAmp reimbursement efforts.

Veracyte stated that it had already factored the ongoing operating expenses of Convergent into its previously provided 2026 adjusted EBITDA guidance. Consequently, the company is not updating its financial outlook at this time.

What The Numbers Show

The deal structure reveals a clear risk-reward split. Veracyte is committing $150 million in immediate capital to secure clinical validation already achieved in NMIBC. The remaining $30 million is strictly tied to commercialization hurdles, specifically reimbursement. This suggests that while the clinical utility is established, the primary value driver—and risk—lies in securing payer coverage rather than further clinical trials.